Human liver-like three-dimensional structure, method for evaluating hepatotoxicity, and human liver-like complex
A human liver-like three-dimensional structure using human hepatocytes and other human cells addresses the issue of mouse-derived cell interference in existing models, enabling accurate hepatotoxicity evaluation through miRNA analysis in exosomes.
Patent Information
- Application Number
- JP2021502202
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-02-22
- Filing Date
- 2020-02-21
- Publication Date
- 2024-12-09
- Estimated Expiration
- 2040-02-21
AI Technical Summary
Existing human liver models for drug toxicity testing contain mouse-derived cells, leading to inaccurate negative controls due to unaccounted mouse-specific metabolic effects, complicating drug evaluation results.
A human liver-like three-dimensional structure composed of human hepatocytes and other human-derived cells, such as hepatic stellate cells, is created through co-culture to form heterospheroids, which are then stacked or blended, ensuring human-specific toxicity evaluation without mouse-derived cell interference.
The structure accurately mimics human liver functions and enables simple, effective hepatotoxicity evaluation by measuring miRNA in exosomes, providing a reliable tool for drug toxicity testing.
Smart Images

Figure 0007595939000008 
Figure 0007595939000009 
Figure 0007595939000010
Abstract
Description
[Technical field]
[0001] The present invention relates to a human liver-like three-dimensional structure including a heterospheroid, a method for evaluating hepatotoxicity using said structure, and a human liver-like complex in which two or more of said structures are linked together. [Background technology]
[0002] Pharmaceutical companies have a high need for in vitro human liver models to narrow down drug candidate compounds for toxicity and metabolite testing in clinical trials, which are costly and time-consuming. Human liver models that can predict toxicity in clinical trials are expected to be a tool to streamline and accelerate drug discovery research.
[0003] Currently, one of the existing methods for producing an in vitro human liver model is a method in which hepatocytes are co-cultured with mouse fibroblasts to enhance their functionality (Non-Patent Documents 1 and 2).
[0004] However, the human liver models obtained by these methods contain mouse-derived cells in addition to human hepatocytes. Therefore, it was necessary to consider the influence of the mouse-specific metabolic system in drug toxicity tests and metabolite evaluation. In this case, a method using only mouse-derived cells as a negative control was adopted, but since the influence of co-culture on mouse cells was not taken into consideration, strictly speaking it is difficult to call it an accurate negative control, and the influence of mouse cells on the obtained drug evaluation results could not be completely eliminated.
[0005] Patent Document 1 proposes a human liver-like three-dimensional structure produced using human hepatocytes and human-derived cells other than human hepatocytes. The human liver-like three-dimensional structure of Patent Document 1 makes it possible to accurately and easily evaluate human-specific toxicity and the like without having to consider the influence of the mouse-specific metabolic system, which was a concern in the co-culture system using human hepatocytes and mouse fibroblasts, but there is still room for improvement. [Prior art documents] [Patent documents]
[0006] [Patent Document 1] International Publication No. 2017 / 200111 [Non-patent literature]
[0007] [Non-Patent Document 1] Khetani SR et al., Nat. Biotechnol. 26: 120-126 (2008) [Non-Patent Document 2] Ohkura T. et al., Drug Metab. Pharmacokinet. 29: 373-378 (2014) Summary of the Invention [Problem to be solved by the invention]
[0008] There is a need for a human liver-like three-dimensional structure that enables accurate and easy evaluation of human-specific toxicity, etc. [Means for solving the problem]
[0009] That is, the present invention is as follows. [1] A human liver-like three-dimensional structure comprising a heterospheroid formed by aggregating human hepatocytes and human-derived cells other than human hepatocytes, the other human-derived cells are at least one selected from the group consisting of human hepatic stellate cells, human lung fibroblasts, human aortic adventitial fibroblasts, human periodontal ligament fibroblasts, human intestinal myofibroblasts, human tendon cells, human astrocytes, human neonatal skin fibroblasts, human synovial stromal cells, human brain capillary pericytes, human renal mesangial cells, human cardiac fibroblasts, human aortic vascular smooth muscle cells, human osteoblasts, normal human skeletal muscle cells, human dental pulp stem cells, human nucleus pulposus cells, human annulus fibrosus cells, human ligament cells, human chondrocytes, human Kupffer cells, human sinusoidal endothelial cells, human bile duct epithelial cells, human adult skin fibroblasts, human bone marrow-derived mesenchymal stem cells, and human adipose-derived mesenchymal stem cells; the ratio of the number of cells derived from the other human to the number of human hepatocytes is 0.01 or more and less than 1; A human liver-like three-dimensional structure. [2] The human liver-like three-dimensional structure described in [1] above, in which the heterospheroids are layered or mixed. [3] The human liver-like three-dimensional structure according to [1] or [2] above, wherein the human hepatocytes and the other human-derived cells are uniformly distributed. [4] The human liver-like three-dimensional structure described in [3] above, wherein the other human-derived cells include human hepatic stellate cells. [5] The human liver-like three-dimensional structure described in [4] above, wherein the aggregation portion where the human hepatic stellate cells are aggregated has a projected area equivalent circle diameter of up to 100 μm. [6] The human liver-like three-dimensional structure according to any one of the above [1] to [5], wherein the heterospheroid has a projected area equivalent circle diameter of 300 to 1000 μm. [7] The human liver-like three-dimensional structure according to the above [6], wherein the heterospheroid has a projected area equivalent circle diameter of 400 to 600 μm. [8] The human liver-like three-dimensional structure according to any one of the above [1] to [7], which is approximately spherical and has a projected area equivalent circle diameter of at least 1.0 mm. [9] The human liver-like three-dimensional structure according to the above [8], which is approximately spherical and has a projected area circle equivalent diameter of 1.1 to 10.0 mm.
[10] The human liver-like three-dimensional structure according to the above [9], which is approximately spherical and has a projected area equivalent circle diameter of 1.2 to 5.0 mm.
[11] A hollow or solid, approximately cylindrical or approximately polygonal prism, The human liver-like three-dimensional structure according to any one of the above [1] to [7], which has an average cross-sectional diameter of 1.0 to 10.0 mm.
[12] It is ring-shaped. The human liver-like three-dimensional structure according to any one of the above [1] to [7], wherein the average minor axis of the bottom and top surfaces is 1.0 to 10.0 mm.
[13] The human liver-like three-dimensional structure according to any one of the above [1] to [7], which is in the form of a sheet having an average thickness of at least 300 μm.
[14] The human liver-like three-dimensional structure according to the above
[13] , which is in the form of a sheet having an average thickness of at least 500 μm.
[15] A method for evaluating the hepatotoxicity of a test substance in humans, comprising: (1) a contacting step of contacting the test substance with the human liver-like three-dimensional structure according to any one of [1] to
[14] above; and (2) a measuring step for measuring the presence or absence of damage to the human liver-like three-dimensional structure or the degree of the damage; A method comprising:
[16] The method according to
[15] above, wherein the measuring step includes an exosome recovery step of recovering exosomes released from the three-dimensional structure, and an miRNA analysis step of analyzing miRNA contained in the exosomes.
[17] The method for evaluating liver toxicity described in
[15] or
[16] above, wherein the miRNA analysis step is performed by microarray or PCR.
[18] A human liver-like complex comprising two or more of the human liver-like three-dimensional structures according to any one of [1] to
[14] above linked together.
[19] The human liver-like three-dimensional structure according to any one of [1] to
[14] above, which is formed by fusing two or more of the heterospheroids.
[20] The human liver-like three-dimensional structure according to any one of [4] to
[14] above, wherein the other human cells include human hepatic stellate cells, and the human hepatic stellate cells are in a quiescent state.
[21] A method for evaluating the hepatotoxicity of a test substance in humans, comprising: (1) a contacting step of contacting the test substance with the human liver-like three-dimensional structure described in
[20] above; and (2) a measuring step for measuring the presence or absence of damage to the human liver-like three-dimensional structure or the degree of the damage; A method comprising:
[22] A step of mixing and culturing human hepatocytes and other human-derived cells other than human hepatocytes in amounts such that the ratio of the number of the other human-derived cells to the number of the human hepatocytes is 0.01 or more and less than 1, thereby obtaining a heterospheroid in which the human hepatocytes and the other human-derived cells are aggregated; and The heterospheroids are mixed or layered, The method for producing a human liver-like three-dimensional structure, wherein the other human-derived cells are at least one selected from the group consisting of human hepatic stellate cells, human pulmonary fibroblasts, human aortic adventitial fibroblasts, human periodontal ligament fibroblasts, human intestinal myofibroblasts, human tendon cells, human astrocytes, human neonatal skin fibroblasts, human synovial stromal cells, human brain capillary pericytes, human renal mesangial cells, human cardiac fibroblasts, human aortic vascular smooth muscle cells, human osteoblasts, normal human skeletal muscle cells, human dental pulp stem cells, human nucleus pulposus cells, human annulus fibrosus cells, human ligament cells, human chondrocytes, human Kupffer cells, human sinusoidal endothelial cells, human bile duct epithelial cells, human adult skin fibroblasts, human bone marrow-derived mesenchymal stem cells, and human adipose-derived mesenchymal stem cells.
[23] A human liver-like three-dimensional structure obtained by the production method described in
[22] above. Effect of the Invention
[0010] The present invention provides a human liver-like three-dimensional structure capable of exerting a function similar to that of the liver in the human body, and a method for evaluating the hepatotoxicity of a test substance to humans using the human liver-like three-dimensional structure. Also provided is a human liver-like complex comprising a plurality of linked human liver-like three-dimensional structures. [Brief description of the drawings]
[0011] [Figure 1] FIG. 1 shows the results of gene expression analysis of human liver-like three-dimensional structure A in Experimental Example 4. [Diagram 2] FIG. 13 shows the results of gene expression analysis of human liver-like three-dimensional structure B in Experimental Example 4. [Diagram 3] FIG. 13 is a graph showing changes in albumin concentration in the medium in Experimental Example 5. [Figure 4] FIG. 13 is a graph showing changes in the amount of ATP contained in a human liver-like three-dimensional structure in Experimental Example 5. [Diagram 5] 1 shows an immunostained image of a human liver-like three-dimensional structure in Experimental Example 5. [Figure 6]FIG. 13 shows the results of measuring the number of exosome particles and particle size distribution in Experimental Example 6. [Figure 7] 1 is a graph showing the activity of CYP3A4 enzyme in human liver-like three-dimensional structure A in Experimental Example 4'. [Figure 8] FIG. 13 shows the toxicity detection results in Experimental Example 5'. [Figure 9] 13 shows mass chromatograms of each metabolic product when phenytoin was administered to a human liver-like three-dimensional structure in Experimental Example 7. [Figure 10] 13 shows mass chromatograms of each metabolic product when torcetrapib was administered to a human liver-like three-dimensional structure in Experimental Example 8. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0012] The present invention will be described in detail below. The following embodiments are merely illustrative for explaining the present invention, and are not intended to limit the present invention to these embodiments. The present invention can be embodied in various forms without departing from the gist of the present invention. All documents cited in this specification, as well as published publications, patent publications and other patent documents, are hereby incorporated by reference.
[0013] The present invention relates to a human liver-like three-dimensional structure comprising a heterospheroid in which human hepatocytes and other human-derived cells other than human hepatocytes are aggregated. The cells contained in the heterospheroid are of human origin, and do not contain mouse-derived cells. In the present invention, it is only necessary to co-culture human hepatocytes with other human-derived cells such as human hepatic stellate cells, thereby producing a human liver model with high liver function.
[0014] 1.Culture conditions In the present invention, human-derived hepatocytes (first cells) are co-cultured with human-derived cells other than the hepatocytes (second cells) to prepare spheroids in which the hepatocytes and human-derived cells are mixed. Since the prepared spheroids contain a mixture of different types of cells, the spheroids are called "hetero-spheroids". However, in this specification, they are also simply called "spheroids".
[0015] The hepatocytes (also called Hep) used in the present invention are cells derived from humans, and biopsied hepatocytes, commercially available frozen hepatocytes, etc. can be used. In addition, hepatocytes induced to differentiate from ES cells, iPS cells, cells derived from living organisms, etc. using reagents, genes, mRNA, microRNA, etc., reprogrammed hepatocytes, etc. can also be used.
[0016] On the other hand, the second cells used in the present invention, which are human-derived cells other than human hepatocytes, are at least one selected from the group consisting of human hepatic stellate cells, human lung fibroblasts, human aortic adventitial fibroblasts, human periodontal ligament fibroblasts, human intestinal myofibroblasts, human tendon cells, human astrocytes, human neonatal skin fibroblasts, human synovial stromal cells, human brain capillary pericytes, human renal mesangial cells, human cardiac fibroblasts, human aortic vascular smooth muscle cells, human osteoblasts, normal human skeletal muscle cells, human dental pulp stem cells, human nucleus pulposus cells, human annulus fibrosus cells, human ligament cells, human chondrocytes, human Kupffer cells, human sinusoidal endothelial cells, human bile duct epithelial cells, human adult skin fibroblasts, human bone marrow-derived mesenchymal stem cells, and human adipose-derived mesenchymal stem cells. These second cells may be of normal or pathological origin. The second cell may be a cell obtained by inducing differentiation of an ES cell, an iPS cell, a cell derived from a living body, etc., using a reagent, a gene, an mRNA, a microRNA, etc., or a reprogrammed cell. In addition, the second cell may be a commercially available cell, or may be prepared from human tissue by enzymatic or physical treatment.
[0017] The second cells preferably include at least one selected from the group consisting of human hepatic stellate cells, human Kupffer cells, human sinusoidal endothelial cells, human bile duct epithelial cells, human adult dermal fibroblasts, and human adipose-derived mesenchymal stem cells, and particularly preferably include human hepatic stellate cells.
[0018] The first and second cells are cultured or maintained in a medium suitable for each of the cells and mixed. When cultured after mixing, the first and second cells aggregate to form a cell aggregate, i.e., a heterospheroid.
[0019] In the present invention, the culture medium for the first cells may be a medium generally used for culturing hepatocytes. Examples of such a medium include DMEM, RPMI-1640, DMEM / F12, Williams' Medium E, etc. In addition, commercially available hepatocyte culture medium (Primary Hepatocyte Maintenance Supplements (CM series, Life Technologies)) and the like may also be used.
[0020] The medium for the second cells is appropriately selected according to the type of each cell. For example, the culture medium for human osteoblasts (NHOST) is OGM Bullet Kit (Lonza), the culture medium for normal human tendon cells (TEN) is Tenocyte Growth Medium (Zenbio), the culture medium for normal human brain capillary pericytes (HBMPC) is CSC Complete Recombinant Medium (Cell Systems Corporation), the culture medium for normal human bile duct epithelial cells (IHBEC) is Intra-Hepatic Biliary Epithelial Cell Growth Medium (Zenbio), and the culture medium for normal human sinusoidal endothelial cells (SEC) is Prigrow I (Applied Biological Materials Inc.).
[0021] The medium may contain, for example, various antibiotics and serum such as fetal bovine serum.
[0022] Here, "mixing" is not particularly limited as long as it is a situation in which the first cell and the second cell can come into contact with each other, and examples include (i) a mode in which a cell suspension of each cell is placed in one container and mixed, (ii) a mode in which a cell suspension of the first cell and the second cell is added to one of the culture containers of the other cell, and (iii) a mode in which one cell is allowed to adhere or settle in the culture container, all or part of the medium is removed, and a cell suspension of the other cell is added to the culture medium.
[0023] Regarding the mixing ratio of cells for producing heterospheroids, the number of first cells (hepatocytes) is greater than the number of second cells (human-derived cells other than hepatocytes). Preferably, the ratio of second cells to first cells (second cells / first cells) is 0.01 to 1.0. More preferably, it is 0.01 or more and less than 1, and even more preferably, it is 0.02 to 0.5. Most preferably, it is 0.05 to 0.1.
[0024] The concentration of the first cells in the co-culture medium should be at least 0.4 x 10 5 0.6×10 5 ~2.0×10 5 0.8×10 cells / ml is more preferable. 5 ~1.2×10 5 It is preferable to prepare the second cells so that the cell number of the first cells meets the above-mentioned ratio, and then mix the two. The above concentration ranges refer to the concentrations before the start of co-culture.
[0025] 3. Measurement and Selection Indicators The ability to form spheroids can be examined by morphological examination using an optical microscope. In addition, whether or not the spheroid has a predetermined function can be examined by using gene expression in the spheroid as an index. The genes used as the index are not particularly limited, but it is preferable to use liver function-related genes, drug metabolism-related genes, etc. As the drug metabolism-related genes, for example, CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP2E1, GSTM1, GSTT1, SULT2A1, UGT1A1, UGT2B4, BCRP, BSEP, MRP2, MATE1, MRP6, MDR1, NTCP, OCT1, OATP1B1, OATP1B3, etc. are preferable. As the liver function-related genes, HNF1A, HNF3A, HNF4A, HNF6, PROX1, CEBPA, CAR, ALB, etc. are included. However, the drug metabolism-related genes and liver function-related genes are not limited to these.
[0026] The gene expression can be confirmed by general techniques such as RT-PCR and Northern blotting, either alone or in appropriate combination.
[0027] Alternatively, whether or not a spheroid has a given function may be evaluated using indicators such as the amount of ATP, albumin secretion, ammonia metabolism, urea production, drug metabolism, and protein expression.
[0028] 4. Production of human liver-like constructs In the present invention, a human liver-like three-dimensional structure can be prepared by blending or stacking the spheroids formed as described above.
[0029] The method for three-dimensionally combining or stacking the spheroids is not particularly limited. For example, a method for three-dimensionally combining the spheroids includes a method of placing the spheroids in a tube or the like and culturing them. As a result, the spheroids fuse together to form a larger mass of spheroids, which becomes the human liver-like three-dimensional structure of the present invention.
[0030] Also, a method is known in which spheroids are arranged in an arbitrary three-dimensional space and stacked to produce a three-dimensional structure of cells (WO2008 / 123614). In this method, needle-shaped objects are arranged on a substrate in a pinholder shape, and the cell clusters are pierced by the needle-shaped objects, or the cell clusters are pierced by the needle-shaped objects, thereby arranging the spheroids. This method makes it possible to obtain a scaffold-free three-dimensional structure. In this specification, the term "stacking" refers to forming a structure by arranging a total of 2 or more, preferably 9 or more, spheroids in the vertical, horizontal and height directions.
[0031] In the present invention, it is preferable to prepare a liver-like three-dimensional structure (three-dimensional structure) by utilizing the above-mentioned method using needle-shaped bodies. Since an automatic stacking robot for implementing the above-mentioned method is already known (bio 3D printer "Legenova" (registered trademark) and "S-PIKE" (registered trademark), both of which are manufactured by Cyfuse Co., Ltd.), it is preferable to use this robot.
[0032] Here, an example of the above-mentioned preferred method will be briefly described. In this preferred method, the human liver-like three-dimensional structure of the present invention is produced, for example, by steps I to IV using an automatic stacking robot "Regenova" (registered trademark).
[0033] In step I, the above-mentioned spheroids are provided. The size of the spheroids to be provided is preferably 300 to 1000 μm, more preferably 300 to 800 μm, and particularly preferably 400 to 600 μm, in terms of the projected area circle equivalent diameter. The projected area equivalent diameter is the diameter of a circle equivalent to the projected area as observed by an optical microscope. When using the automatic stacking robot described above, it can be measured using the measurement function installed in the device. In other cases, it can be measured using a stereo microscope.
[0034] Steps II and III are approaches to fabricating precursor structures using a pinholder-type bioprinting. In step II, spheroids are stacked using a pinholder (e.g., made of stainless steel or tungsten) at a specified pitch.
[0035] Step III is a perfusion culture process in which the spheroids are stuck into the pinholder, and the stacked spheroids fuse to form a bioprinting structure such as a dice or patch. The flow rate of the medium in the perfusion culture process is preferably 1 to 4 ml / min. In perfusion culture, it is recommended to use a dedicated circulation culture device (e.g., Cyfuse, product name: Perfusion culture device type 1 PC1004) from the viewpoint of efficient supply of medium components.
[0036] In step IV, after confirming that the spheroids have fused with each other after the perfusion culture, the structure precursor is pulled out from the pinholder, and the pulled out structure precursor is cultured with shaking to obtain the desired human liver-like three-dimensional structure.
[0037] The above steps I to IV are merely examples, and as long as the human liver-like three-dimensional structure of the present invention can be obtained, the content of the steps may be appropriately changed, steps may be omitted, or steps may be added.
[0038] For example, in step II, instead of piercing the spheroid with the pinholder, the pinholder may be pierced into the spheroid. In step III, shaking culture may be performed instead of perfusion culture. Also, in step III, the culture system may be irradiated with ultrasound during culture. In step IV, shaking culture or perfusion culture may be performed without removing the structure from the pinholder.
[0039] The number and shape of the spheroids to be arranged are not particularly limited and may be arbitrarily chosen.
[0040] When human hepatic stellate cells are used as the second cells, it is preferable to add a stellate cell quiescent agent that converts human hepatic stellate cells from an activated state to a quiescent state (also called an inactivated state) to the medium components during production. As used herein, quiescence refers to a state in which a cell is not dividing. A cell in the G0 phase of the cell cycle can be said to be in a quiescent state.
[0041] Human hepatic stellate cells (HSCs) are fibroblasts that exist in the space between hepatocytes and sinusoidal endothelial cells, known as the space of Disse, in the human liver. Human HSCs are distinct from other cells in the liver in that they express the receptor platelet-derived growth factor receptor-β (PDGFRβ), the enzyme lecithin retinol acyltransferase (LRAT), the cytoskeletal proteins desmin and glial fibrillary acidic protein, and the transcription factors heart-and neural crest derivatives-expressed proteins, globin, and cytoglobin (CYGB). HSCs become activated during liver injury or primary culture, and transform into myofibroblast (MFB)-like cells. In the human liver, activated HSCs proliferate, participate in inflammatory responses, and produce fibrosis-inducing factors such as transforming growth factor-β (TGF)-β while overproducing ECM, which plays a key role in fibrosis. In the human body, stellate cells are in a quiescent state in normal livers where no inflammation is occurring.
[0042] Human hepatic stellate cells are in an activated state under normal culture conditions. That is, human hepatic stellate cells under normal culture conditions exhibit high proliferation and fibrosis, and are in a state comparable to that of a living liver when some inflammation occurs. Therefore, when used for hepatotoxicity evaluation, the human liver-like three-dimensional structure of this embodiment is preferably in a state close to that of a normal liver. In addition, although the production of ECM facilitates the formation of a human liver-like three-dimensional structure, if an excessive amount of ECM is present in the structure after the human liver-like three-dimensional structure is completed, it may affect the evaluation of liver toxicity, etc. Therefore, when producing a human liver-like three-dimensional structure, it is preferable to use a stellate cell quiescent agent to quiesce human stellate cells.
[0043] In the present invention, the cell quiescent agent can be selected from a group of compounds known as quiescent (inactivating) agents for stellate cells, such as TGFβ inhibitors A83-01, SB-431542, SB-505124, and SB-522334; angiogenesis inhibitor TNP-470; LDHA inhibitor FX-11; and glycolysis inhibitor 2-deoxyglucose.
[0044] The addition of the stellate cell quiescent agent may be performed at any timing between the start of spheroid formation and the evaluation of hepatotoxicity, depending on the type of agent and culture conditions. However, quiescence of stellate cells takes time after the addition of the quiescent agent, and if the timing of the quiescent state is too early, although the activity of the structure immediately after production is high, the sustainability of the activity may be impaired. Therefore, it is preferable to add the quiescent agent after the second day from the start of spheroid formation and before the start of hepatotoxicity evaluation. In the case of the example of the preferred method including the above-mentioned steps I to IV, it is particularly preferable to add the stellate cell quiescent agent at the following timing. - The second day after the initiation of spheroid formation in step I; At the start of Phase III; or At the start of shaking culture of the extracted structure precursor after the structure precursor is pulled out from the pin holder in step IV.
[0045] The concentration of the stellate cell quiescent agent in the medium is preferably within the range of 0.1 to 3 (μmol / l).
[0046] Since it takes time (usually about 2 to 7 days, depending on the culture conditions) for astrocytes to become quiescent after the addition of the astrocyte quiescent agent, if the medium is to be changed during this period, it is preferable to change to a medium containing an astrocyte quiescent agent.
[0047] To confirm that stellate cell quiescence has been achieved, it is preferable to use the expression of α-SMA (ACTA2) as a marker for the gene of the spheroid or structure. In this case, it can be determined that hepatic stellate cells have been quiesced when the expression level of the α-SMA gene is reduced to 1 / 10 to 1 / 100 of that before the addition of the quiescent agent. It is preferable to complete the conversion of hepatic stellate cells to a quiescent state before starting the evaluation of hepatotoxicity.
[0048] 5. Human liver-like structure The human liver-like three-dimensional structure of the present invention can be free of a scaffold, and cells can adhere to each other directly or via an extracellular matrix or E-cadherin. The extracellular matrix in the human liver-like three-dimensional structure of the present invention preferably contains 1-3% by mass of type I collagen and 1-3% by mass of type III collagen, based on dry weight. When E-cadherin is mediated, E-cadherin tends to be localized at the interface between hepatocytes or at the junction of a bile duct-like structure, etc. Both the extracellular matrix and E-cadherin are derived from the cells that make up the human liver-like three-dimensional structure.
[0049] Furthermore, the human liver-like three-dimensional structure of the present invention has more first cells than second cells when completed, and the ratio of the number of second cells (cells derived from another human) to the number of first cells (human hepatocytes) is not less than 0.01 and less than 1, preferably 0.01 to 0.1, and more preferably 0.01 to 0.05.
[0050] In the human liver-like three-dimensional structure of the present invention, it is preferable to distribute the first cells and the second cells uniformly by adjusting the co-culture conditions, the type of cells used, etc. More preferably, the first cells and the second cells are distributed uniformly under the condition that the second cells contain human hepatic stellate cells.
[0051] Whether the first cells and the second cells are uniformly distributed can be determined by the following method. That is, the human liver-like three-dimensional structure is fixed with formalin and solidified with paraffin to prepare a tissue block. Sections are cut from the obtained block to prepare tissue sections. The obtained tissue sections are subjected to HE staining and immunostaining, and photographed. For immunostaining, a primary antibody that recognizes the first cells and a primary antibody that recognizes the second cells are preferably used. For example, it is preferable to use an anti-albumin antibody for hepatocytes. When the second cells include hepatic stellate cells, it is preferable to use an anti-desmin antibody that recognizes hepatic stellate cells. For the obtained stained image, the areas of the first cell region and the second cell region are measured for each 200 μm × 200 μm region, and the area ratio R of the first cell region to the second cell region is calculated using the following formula. R = (area of second cell) / {(area of second cell)+(area of first cell)}×100(%) When a histogram of the area ratio R (%) measured in each region is distributed according to a normal distribution and the standard deviation (σ) of R is less than 3.0, particularly 1.5 to 2.0, it is determined that the first cells and the second cells are uniformly distributed.
[0052] Furthermore, provided that the histogram of the area ratio R is distributed according to a normal distribution and σ satisfies the above-mentioned numerical range, it is particularly preferable that the aggregation area of second cells such as human hepatic stellate cells has a projected area equivalent circle diameter of up to 100 μm, particularly 20 to 100 μm.
[0053] The human liver-like three-dimensional structure of the present invention can have a large size even though it can be made scaffold-free. According to the preferred production method described above, it is possible to prepare a large human liver-like three-dimensional structure without using a scaffold.
[0054] For example, when the human liver-like three-dimensional structure of the present invention is approximately spherical, the projected area equivalent circle diameter is preferably at least 1.0 mm, more preferably 1.1 to 10.0 mm, and particularly preferably 1.2 to 5.0 mm.
[0055] When the human liver-like three-dimensional structure of the present invention is a hollow or solid roughly cylindrical structure, the diameter of the cross section (the outer circumference of the cross section in the case of a hollow structure) when cut at three equally spaced positions in the length direction is preferably 1.0 to 10.0 mm, more preferably 1.2 to 5 mm, on average. When the cross section is an ellipse or the like having a distortion, the "diameter of the cross section" is measured as the minor axis of the cross section.
[0056] When the human liver-like three-dimensional structure of the present invention is a hollow or solid approximately polygonal column, the diameter of the circumscribed circle of a cross section (the outer periphery of the cut surface in the case of a hollow structure) when cut at three equally spaced points in the length direction is preferably 1.0 to 10.0 mm, more preferably 1.2 to 5 mm, on average. When the circumscribed circle is a distorted ellipse or the like, the "diameter of the circumscribed circle" is measured as the minor axis of the circumscribed circle.
[0057] When the human liver-like three-dimensional structure of the present invention is in the shape of a ring, the average value of the diameter of the peripheral circle of the bottom surface and the diameter of the peripheral circle of the top surface is preferably 1.0 to 10.0 mm, and more preferably 1.2 to 5 mm. When the peripheral circle is an ellipse or the like having a distortion, the "diameter of the peripheral circle" is measured as the minor axis of the peripheral circle.
[0058] In this specification, a ring shape refers to a shape in which the length of the body is shorter than the diameter of the outer circumferential circle of the base. If the length of the body is equal to or greater than the diameter of the outer circumferential circle of the base, it is classified as a hollow cylindrical shape.
[0059] The human liver-like three-dimensional structure of the present invention can also be made into a sheet by arranging heterospheroids in a planar direction. Since heterospheroids are larger than single cells, the sheet obtained by arranging heterospheroids in a planar direction is also a three-dimensional sheet having a certain degree of thickness. The thickness is preferably at least 300 μm on average, more preferably at least 500 μm, and particularly preferably 500 to 1000 μm. The thickness can be measured by an optical microscope.
[0060] Whether or not the human liver-like three-dimensional structure of the present invention can function as a liver model can be determined by the same method as that described as the selection index for spheroids in the above-mentioned 3. Measurement and Selection Index. Preferred genes to be used as indicators are phase 1 enzyme genes in drug metabolism such as CYP3A4, CYP1A2, CYP2D6, CYP2C9, etc.; phase 2 enzyme genes in drug metabolism such as UGT1A1, etc.; or transporter genes such as OATP1B1, OATP1B3, etc.
[0061] In addition, as an indicator specific to the human liver-like three-dimensional structure, the oxygen concentration inside the structure may be monitored using a detection fluorescent probe (MAR, Goryo Chemical).
[0062] Furthermore, based on the knowledge that exposure to rifampicin increases the expression of CYP3A4 enzyme in hepatocytes in vivo, the expression level of CYP3A4 may be confirmed by contacting the human liver-like three-dimensional structure with rifampicin.
[0063] The human liver-like three-dimensional structure of the present invention maintains functions similar to those of the human liver even after long-term culture, and also has a high survival rate.
[0064] The human liver-like three-dimensional structure of the present invention can be used as a liver model for various purposes such as evaluation of metabolism of a test substance in the human body and evaluation of hepatotoxicity of a test substance to humans.
[0065] For example, when evaluating metabolism, a test substance described below is contacted with the human liver-like three-dimensional structure of the present invention, and when a metabolic product of the test substance is detected as a reaction product inside or outside the structure, the test substance is determined to have been metabolized. Examples of metabolic products of the test substance include phase I metabolic products and phase II metabolic products of the test substance. For detection, known means such as LC / MS / MS can be used.
[0066] The human liver-like three-dimensional structure of the present invention preferably contains human hepatic stellate cells as the second cells, and the human hepatic stellate cells are in a quiescent state.
[0067] The human liver-like three-dimensional structure of the present invention is preferably used in a method for evaluating the hepatotoxicity of a test substance to humans.
[0068] 5. Human liver-like complex The human liver-like three-dimensional structure of the present invention may be used for various purposes as it is, or may be fused to form a human liver-like complex by linking two or more human liver-like three-dimensional structures. The human liver complex of the present invention may be used for the same purposes as the human liver-like three-dimensional structure.
[0069] 6. Methods for assessing hepatotoxicity An example of a method for evaluating the hepatotoxicity of a test substance in humans is a method comprising the following steps (1) and (2). Hereinafter, this method may be referred to as the "method for evaluating hepatotoxicity of the present invention." (1) A contacting step of contacting a test substance with the human liver-like three-dimensional structure of the present invention. (2) A measuring step for measuring the presence or absence of a disorder in the human liver-like three-dimensional structure of the present invention and the degree of the disorder.
[0070] The test substance used in the method for evaluating hepatotoxicity of the present invention is not particularly limited, and may be, for example, a natural compound, an organic compound, an inorganic compound, a polymeric compound, a protein, a peptide, a compound library, an expression product of a gene library, a cell extract, a cell culture supernatant, a product of fermentation microorganisms, an extract of marine organisms, an extract of plants, or a xenobiotic such as a drug or a food additive containing these. In this specification, the term "xenobiotic" includes any substance as long as it is a foreign substance to a living body. In addition, a drug delivery system may be examined using a xenobiotic and a liposome or a synthetic polymer.
[0071] Examples of drugs include small molecule drugs with a molecular weight of 2,000 or less; medium molecule drugs with a molecular weight of more than 2,000 (approximately several thousand), or some consisting of peptides; antibody drugs or polymer drugs that are bound to polymers; nucleic acid drugs such as antisense oligonucleotides, RNAi, aptamers, and decoys; and cellular drugs represented by somatic stem cells.
[0072] Specific examples of the drug compounds include rifampicin, dexamethasone, phenobarbital, ciglitazone, phenytoin, efavirenz, simvastatin, β-naphthoflavone, omeprazole, clotrimazole, 3-methylcholanthrene, acetaminophen, trovafloxacin, estrone, nifedipine, diclofenac, indomethacin, methotrexate, troglitazone, CCl4, paracetamol, halothane, and amphetamine. Examples include miodarone, thioridazine, methyldopa, isoniazid, levofloxacin, stavudine, felbamate, cyclophosphamide, pioglitazone, rosiglitazone, ketoconazole, perihexiline, benoxaprofen, acetaminophen, clomipramine, fenofibrate, imipramine, zileuton, troglitazone, albendazole, fluconazole, glafemidine, grisoflavine, labetalol, and the like.
[0073] In the contact step (1), the contact between the human liver-like three-dimensional structure and the test substance is usually performed by adding the test substance to a medium or a culture solution, but is not limited to this method. When the test substance is a protein, etc., the contact can also be performed by introducing a DNA vector expressing the protein into the cells.
[0074] In the measurement step (2), the presence or absence of damage to the human liver-like three-dimensional structure of the present invention or the degree of damage is measured. The presence or absence of damage or the degree of damage can be measured using, for example, the viability of hepatocytes, liver damage markers, and exosomes as indicators. It can also be confirmed by HE staining or antibody staining.
[0075] For example, when the test substance is added to the culture medium of the human liver-like three-dimensional structure, the viability of the cells in the human liver-like three-dimensional structure is reduced, the test substance is judged to have hepatotoxicity. When there is no significant change in the viability, the test substance is judged not to have hepatotoxicity. The viability can be confirmed, for example, by measuring ATP activity.
[0076] Examples of liver damage markers include ALT, AST, albumin, and urea. For example, if the ALT or AST in the culture medium increases after adding a test substance to the culture medium of the human liver-like three-dimensional structure, the test substance is determined to have hepatotoxicity. If there is no significant change in ALT or AST, the test substance is determined to have no hepatotoxicity. In addition, if the amount of albumin or urea in the culture medium decreases after adding a test substance to the culture medium of the human liver-like three-dimensional structure, the test substance is determined to have hepatotoxicity. If there is no significant change in albumin or urea, the test substance is determined to have no hepatotoxicity.
[0077] Exosomes are ultra-small membrane vesicles with a diameter of about 30 to 100 nm that are released outside cells in vivo. By monitoring the number, size, and encapsulated components of exosomes released into the medium, the presence or absence of liver toxicity and its degree can be measured.
[0078] The components to be monitored include miRNA and proteins. In particular, analysis of miRNA encapsulated in exosomes has already been reported in cancer and chronic hepatitis C, where miRNA contained in disease-specific exosomes collected from blood is associated with the pathology and progression of the disease, and its use as a disease biomarker is being considered. In this way, from the viewpoint that miRNA responds to events occurring in cells, it is suitable as a method for determining the presence or absence or the degree of hepatotoxicity.
[0079] The miRNA to be analyzed is not particularly limited as long as the amount secreted from cells changes depending on the level of hepatotoxicity. In addition, as such miRNA, appropriate ones can be selected depending on the type of cells, etc.
[0080] For example, in the case of a human liver-like three-dimensional structure containing human hepatocytes and human hepatic stellate cells using human hepatic stellate cells as the second cells, as described in the Examples below, the secretion of miRNAs consisting of the base sequences shown in SEQ ID NOs: 1 to 6; miR-122, miR-192, and miR-224, into the culture supernatant increases with increasing hepatotoxicity. [Table 1]
[0081] As an index for determining the presence or absence of hepatotoxicity or its level, only one type of miRNA may be measured, or multiple types of miRNA may be measured.
[0082] Steps for measuring miRNA in exosomes released from cells include, for example, the following. (2-1) An exosome recovery step of recovering exosomes released from the three-dimensional structure. (2-2) An miRNA analysis step for analyzing the miRNA contained in exosomes.
[0083] In the exosome recovery step (2-1), for example, a portion of the culture supernatant is sampled, and exosomes are recovered from the sampled culture supernatant by a known method such as ultracentrifugation or the use of a commercially available exosome isolation kit.
[0084] In the miRNA analysis step (2-2), miRNA is first extracted from the collected exosomes by a known method such as using a commercially available miRNA extraction kit. Next, the expression level of a specific miRNA in the total extracted miRNA is measured using known means such as a miRNA microarray, quantitative real-time PCR, or PCR such as digital PCR.
[0085] For a specific miRNA that is known to increase or decrease depending on the degree of hepatotoxicity, the expression level of that miRNA can be compared with the expression level (reference value) of the miRNA secreted by cells not in contact with the test substance to evaluate the degree of hepatotoxicity. In addition to the reference value, an appropriate threshold value can be determined for each type of miRNA, and if the value exceeds or falls below that value, it can be determined that there is hepatotoxicity, etc.
[0086] From the viewpoint of being able to comprehensively confirm the expression profiles of multiple types of miRNA, a microarray for miRNA is preferred.
[0087] In the miRNA recovery step (2-2), a principal component analysis may be performed on the sequence data of the miRNA expression levels detected for each of a plurality of test substances. For example, a correlation diagram between the first principal component PC1 and the second principal component PC2 can be created to confirm the correlation between the toxicity mechanisms of the test substances.
[0088] The method for evaluating hepatotoxicity of the present invention makes it possible to confirm the hepatotoxicity of a test substance that is known to be hepatotoxic in clinical practice but for which the hepatotoxicity cannot be detected by conventional methods. EXAMPLES
[0089] The present invention will be specifically described below by showing experimental examples, but the present invention is not limited to the following experimental examples.
[0090] [Experimental Example 1] Preparation of a precursor for human liver-like three-dimensional structures 1 × 10 frozen human hepatocytes (Cryopreserved Human Hepatocytes, Sekisui XenoTech) were added to a spheroid-making plate (Nunclon Sphera 96-well microplate) that had been treated to prevent cell adhesion. 4 and 5 × 10 human hepatic stellate cells (ScienCell Research Laboratories, Inc.) 2 The cells were seeded at 37°C and 5% CO 2 After culturing for 3 to 5 days under reduced pressure, spheroids with a diameter (equivalent circle diameter of projected area) of 500 μm were obtained. Next, the obtained spheroids were arranged in a three-dimensional cell stacking system Regenova (Cyfuse Corporation), three vertically and three horizontally, for a total of nine spheroids, and cultured for five days in a perfusion culture apparatus.
[0091] Nine spheroids fused to form a single mass, yielding precursor A of the human liver-like three-dimensional structure.
[0092] [Experimental Example 2] Preparation of a precursor for human liver-like three-dimensional structures 1 × 10 frozen human hepatocytes (Cryopreserved Human Hepatocytes, Sekisui XenoTech) were added to a spheroid-making plate (Nunclon Sphera 96-well microplate) that had been treated to prevent cell adhesion. 4 and 5 × 10 human hepatic stellate cells (ScienCell Research Laboratories, Inc.) 2 The cells were seeded at 37°C and 5% CO 2 After culturing for 3 to 5 days under reduced pressure, spheroids with a diameter (equivalent circle diameter of projected area) of 500 μm were obtained. Next, using the obtained spheroids and the three-dimensional cell stacking system Regenova (Cyfuse Co., Ltd.), a total of 27 spheroids were arranged in a matrix of three vertically, three horizontally, and three vertically, and cultured for five days in a perfusion culture device.
[0093] Twenty-seven spheroids fused to form a single mass, yielding precursor B of the human liver-like three-dimensional structure.
[0094] [Experimental Example 3] Creation of a human liver-like three-dimensional structure by shaking culture After removing the precursors A and B prepared in Experimental Example 1 or Experimental Example 2 from the pin holder, they were placed separately in 8 mL Sarstedt tubes containing 1 mL of medium, and then incubated with CO 2 The cells were cultured with shaking in an incubator for 5 days.
[0095] The needle marks of the precursor disappeared during shaking culture, and the shape changed to a spherical shape, obtaining human liver-like three-dimensional constructs A and B. The spherical equivalent diameter of human liver-like three-dimensional construct A was 1.0 mm, and the spherical equivalent diameter of human liver-like three-dimensional construct B was 1.5 mm.
[0096] [Experimental Example 3´] After removing the precursor A prepared in Experimental Example 1 from the pin holder, 1 mL of medium containing the TGFβ inhibitor A83-01 at 3 μmol / L was placed in each of the 8 mL Sarstedt tubes. 2 The cells were cultured in an incubator with shaking for 5 days. The resulting liver-like three-dimensional construct was named liver-like three-dimensional construct A'.
[0097] [Experimental Example 4] Gene expression analysis of human liver-like three-dimensional structure The genes expressed in each of the human liver-like three-dimensional structures A and B prepared in Experimental Example 3, CYP3A4, CYP1A2, CYP2C9, CYP2D6, UGT1A1, MRP2, BSEP, OATP1B1, and OATP1B3, were measured by real-time PCR.
[0098] The results for human liver-like three-dimensional construct A are shown in Figure 1, and those for human liver-like three-dimensional construct B are shown in Figure 2. In the human liver-like three-dimensional constructs A and B produced in Experimental Example 3, the respective genes were continuously expressed for a long period of time, more than 20 days after production and more than 30 days after thawing the raw material frozen liver cells. This was in contrast to the cells cultured on a plate, which died within 7 to 10 days after thawing. The human liver-like three-dimensional structures A and B prepared in Experimental Example 3 were found to be advantageous in that they are able to maintain the liver's inherent functions related to metabolism, conjugation, cellular uptake and excretion at extremely high levels for a long period of time.
[0099] [Experimental Example 4'] CYP3A4 enzyme activity of human liver-like three-dimensional construct A' The activity of the CYP3A4 enzyme in the human liver-like three-dimensional construct A' prepared in Experimental Example 3' was evaluated using a CYP3A4 Activity Assay Kit (Bio Vision). The results are shown in Figure 7. For comparison, the results are shown for a formulation in which the TGFβ inhibitor A83-01 was not added and the stellate cells were not in a quiescent state (Formulation A, which corresponds to the human liver-like three-dimensional construct A prepared in Experimental Example 3). The addition of A83-01 increased CYP3A4 activity by approximately 10-fold, and even after 28 days, this enzyme activity remained at more than 70% of the initial value. It was found that by placing stellate cells in a quiescent state, the metabolic function of the liver structure can be increased and maintained for a long period of time.
[0100] [Experimental Example 5] Evaluation of hepatotoxicity A DMSO solution of trovafloxacin, a drug known to be hepatotoxic when administered to humans, was prepared. The obtained DMSO solution containing the drug was added to the culture medium of the human liver-like three-dimensional structure A prepared in Experimental Example 3 so that the concentration in the medium was 5 to 1000 μmol / l. As a control, a culture medium for the human liver-like three-dimensional structure prepared in Experimental Example 3 to which only the DMSO solution was added was prepared. The change in albumin concentration in the medium up to 24 days after the addition of the drug, and the amount of ATP contained in the structure after the end of the experiment were measured using CellTiter-Glo 3D substrate. Furthermore, tissue sections of the structure were prepared, and HE staining and albumin immunostaining images were obtained.
[0101] The change in albumin concentration in the medium containing trovafloxacin is shown in Figure 3. The change in the amount of ATP contained in the human liver-like three-dimensional structures is shown in Figure 4. The immunostained image of the human liver-like three-dimensional structures is shown in Figure 5. A drug concentration-dependent decrease in albumin concentration was observed, indicating that drug toxicity could be detected. No decrease in albumin concentration was observed in the plate culture system used for comparison (details not provided), demonstrating the superiority of the toxicity evaluation method of the present invention.
[0102] [Experimental Example 5´] Evaluation of hepatotoxicity DMSO solutions of 20 kinds of drugs known to show hepatotoxicity when administered to humans were prepared. The obtained DMSO solutions containing drugs were added to the culture medium of the human liver-like three-dimensional structure A prepared in Experimental Example 3 so that the concentration in the medium was 20 to 50 times the maximum blood concentration (Cmax) of each drug reported in human clinical trials. As a control, a culture medium of the human liver-like three-dimensional structure prepared in Experimental Example 3 to which only the DMSO solution was added was prepared. The change in albumin concentration in the medium 7 and 14 days after the addition of the drug was normalized to 100% when only DMSO was added, and is shown in Figure 8. After 14 days, the concentration was 80% or less, which is a statistically significant difference, compared to when only DMSO was added, for all compounds, demonstrating excellent toxicity detection ability.
[0103] [Experimental Example 6] Evaluation of hepatotoxicity caused by exosomes The culture medium of Experimental Example 5 was centrifuged at 2,000xg for 20 minutes at 4°C, and the collected supernatant was subsequently centrifuged at 15,000xg for 30 minutes. 1.1mL of ExoCap Ultracentrifugation / Storage Booster (registered trademark) and 7.7mL of ultrapure water were added to each 2.2mL of the collected sample solution, and after uniform stirring, each was subjected to ultracentrifugation (35,000rpm, 70min, 4°C). After centrifugation, the supernatant was removed by decantation and aspirator, and then resuspended in ExoCap Ultracentrifugation / Storage Booster (registered trademark) solution diluted 10 times with ultrapure water to obtain 75μL of exosome solution. The number of exosome particles and particle size distribution were measured using qNano (Nanoparticle Multi-Analyzer). In addition, the expression of CD9 was confirmed for the collected exosomes by Western blotting. The miRNA in the sample extracted from the exosomes using an RNA extraction kit was measured by digital PCR. Furthermore, the microRNA contained in the exosomes was extracted, and the amount of miR-122, miR-192, and miR-1 was measured by quantitative PCR. Incidentally, miR-1 is a miRNA that is said to be unrelated to toxicity, and serves as a standard for determining the increase or decrease of miR-122 and miR-192. [Table 2]
[0104] The results are shown in Figure 6. Figure 6(a) shows the particle size distribution of exosomes recovered from the culture medium 3 days after the addition of DMSO alone in Experimental Example 5. Figure 6(b) shows the particle size distribution of exosomes recovered from the culture medium 3 days after the addition of trovafloxacin DMSO solution. Figure 6(c) shows the number and concentration of exosome particles recovered under each condition. An increase in the number and concentration of exosome particles in the medium was observed just 3 days after the addition of the drug. Furthermore, miR-122 was detected from the recovered exosomes.
[0105] The table below shows the results of adding the drugs trovafloxacin, indomethacin, diclofenac, benoxaprofen, zileuton, and troglitazone to the medium, and quantifying the concentration of miR-122-5p detected in exosomes recovered from the medium 3 and 10 days after addition using digital PCR. miR-122-5p was detected when all of the compounds were added, demonstrating that miRNA can be used as an indicator for toxicity evaluation. [Table 3]
[0106] [Experimental Example 7] Chemical structure analysis of metabolic reaction products of phenytoin A DMSO solution of phenytoin was prepared. The obtained DMSO solution containing the drug was added to the culture medium for the human liver-like three-dimensional construct A' prepared in Experimental Example 3' so that the concentration in the medium was 10 μmol / l. The medium was sampled up to 6 days after the addition of the drug, and the metabolic products in the medium were separated and structurally analyzed by LC / MS / MS. Figure 9 shows the mass chromatogram of each metabolic product. The mass numbers used to identify each peak are shown in the table below. Here, the abbreviations for each metabolite indicate the following structures. DPH; 5,5-diphenylhydantoin (phenytoin), DPH-Glu; DPH-N-glucuronide; 4'-HPPH;(4'-hydroxyphenyl)phenylhydantoin, 4'-HPPH-O-Glu;(4'-hydroxyphenyl)phenylhydantoin-O-glucuronide. [Table 4] The four metabolites and the starting material phenytoin were separated and detected by LC. The chemical structures of the metabolites were estimated from the mass spectrometry results obtained by MS / MS measurement of the separated peak positions. The metabolic reaction mechanism of phenytoin finally obtained is shown below. [ka] In this way, the metabolic reactions occurring in the human liver can be predicted in an in vitro evaluation system using this human liver-like three-dimensional structure.
[0107] [Experimental Example 8] Chemical structure analysis of metabolic reaction products of torcetrapib A DMSO solution of torcetrapib was prepared. The obtained DMSO solution containing the drug was added to the culture medium for the human liver-like three-dimensional construct A' prepared in Experimental Example 3' so that the concentration in the medium was 10 μmol / l. The medium was sampled up to 6 days after the addition of the drug, and the metabolic products in the medium were separated and structurally analyzed by LC / MS / MS. Figure 10 shows the mass chromatogram of each metabolic product. The mass numbers used to detect and identify each peak are shown in the table below. [Table 5]
[0108] Two metabolic products, M2 and M5, and the raw material torcetrapib were separated and detected by LC. The chemical structures of the metabolic products were estimated from the mass spectrometry results obtained by MS / MS measurement of each separated peak position. The final metabolic reaction mechanism of torcetrapib is shown below (Drug Metab Dispos. 2008 Oct;36(10):2064-79.). [ka] The metabolic products M2 and M5 are detected when torcetrapib (M) is administered to humans (Drug Metab Dispos. 2010 Oct;38(10):1900-5.). Therefore, this liver-like three-dimensional structure makes it possible to predict the metabolic reactions occurring in the human liver in an in vitro evaluation system.
Claims
1. A human liver-like three-dimensional structure consisting of a heterospheroid formed by aggregating human hepatocytes and human-derived cells other than human hepatocytes, the other human-derived cells are at least one selected from the group consisting of human hepatic stellate cells, human lung fibroblasts, human aortic adventitial fibroblasts, human periodontal ligament fibroblasts, human intestinal myofibroblasts, human tendon cells, human astrocytes, human neonatal skin fibroblasts, human synovial stromal cells, human brain capillary pericytes, human renal mesangial cells, human cardiac fibroblasts, human aortic vascular smooth muscle cells, human osteoblasts, normal human skeletal muscle cells, human dental pulp stem cells, human nucleus pulposus cells, human annulus fibrosus cells, human ligament cells, human chondrocytes, human Kupffer cells, human sinusoidal endothelial cells, human bile duct epithelial cells, human adult skin fibroblasts, human bone marrow-derived mesenchymal stem cells, and human adipose-derived mesenchymal stem cells; the ratio of the number of cells derived from the other human to the number of human hepatocytes is 0.05 to 0.1; A human liver-like three-dimensional structure.
2. The human liver-like three-dimensional structure according to claim 1 , wherein the heterospheroids are layered or mixed.
3. The human liver-like three-dimensional structure according to claim 1 or 2, wherein the human hepatocytes and the other human-derived cells are uniformly distributed.
4. The human liver-like three-dimensional structure according to claim 3, wherein the other human-derived cells include human hepatic stellate cells.
5. The human liver-like three-dimensional structure according to claim 4, wherein the aggregation portion in which the human hepatic stellate cells are aggregated has a maximum projected area equivalent circle diameter of 100 µm.
6. The human liver-like three-dimensional structure according to any one of claims 1 to 5, wherein the heterospheroid has a projected area equivalent circle diameter of 300 to 1000 µm.
7. The human liver-like three-dimensional structure according to claim 6, wherein the heterospheroid has a projected area equivalent circle diameter of 400 to 600 μm.
8. The human liver-like three-dimensional structure according to any one of claims 1 to 7, which is approximately spherical and has a projected area circle equivalent diameter of at least 1.0 mm.
9. The human liver-like three-dimensional structure according to claim 8, which is approximately spherical and has a projected area equivalent circle diameter of 1.1 to 10.0 mm.
10. The human liver-like three-dimensional structure according to claim 9, which is approximately spherical and has a projected area equivalent circle diameter of 1.2 to 5.0 mm.
11. It is a hollow or solid substantially cylindrical or substantially polygonal prism, The human liver-like three-dimensional structure according to any one of claims 1 to 7, wherein the average cross-sectional diameter is 1.0 to 10.0 mm.
12. It is ring-shaped, The human liver-like three-dimensional structure according to any one of claims 1 to 7, wherein the average minor axis of the bottom surface and the top surface is 1.0 to 10.0 mm.
13. The human liver-like three-dimensional structure according to any one of claims 1 to 7, which is in the form of a sheet having an average thickness of at least 300 µm.
14. The human liver-like three-dimensional structure according to claim 13, which is in the form of a sheet having an average thickness of at least 500 μm.
15. A method for evaluating the hepatotoxicity of a test substance in a human, comprising the steps of: (1) A contact step of contacting the test substance with the human liver-like three-dimensional structure according to any one of claims 1 to 14; and (2) measuring the presence or absence of damage to the human liver-like three-dimensional structure or the degree of damage using a combination of a hepatocyte viability based on ATP activity, a liver damage marker selected from ALT, AST, albumin and urea, and miRNA contained in exosomes as indicators; A method comprising:
16. The method according to claim 15, wherein the measuring step of measuring the miRNA contained in the exosome as an indicator comprises an exosome recovering step of recovering the exosome released from the three-dimensional structure, and an miRNA analyzing step of analyzing the miRNA contained in the exosome.
17. The liver toxicity evaluation method according to claim 16 , wherein the miRNA analysis step is carried out by microarray or PCR.
18. A human liver-like complex comprising two or more of the human liver-like three-dimensional structures according to any one of claims 1 to 14 linked together.
19. The human liver-like three-dimensional structure according to any one of claims 1 to 14, which is formed by fusing two or more of the heterospheroids.
20. The human liver-like three-dimensional structure according to any one of claims 4 to 14, wherein the other human cells include human hepatic stellate cells, and the human hepatic stellate cells are in a quiescent state.
21. A method for evaluating the hepatotoxicity of a test substance in a human, comprising the steps of: (1) a contacting step of contacting the test substance with the human liver-like three-dimensional structure according to claim 20; and (2) a measuring step for measuring the presence or absence of damage to the human liver-like three-dimensional structure or the degree of the damage; A method comprising:
22. a step of mixing and culturing human hepatocytes and other human-derived cells other than human hepatocytes in amounts such that the ratio of the number of the other human-derived cells to the number of the human hepatocytes is 0.05 to 0.1, to obtain a heterospheroid in which the human hepatocytes and the other human-derived cells are aggregated; and The method comprises a step of blending or layering the heterospheroids, The method for producing a human liver-like three-dimensional structure, wherein the other human-derived cells are at least one selected from the group consisting of human hepatic stellate cells, human pulmonary fibroblasts, human aortic adventitial fibroblasts, human periodontal ligament fibroblasts, human intestinal myofibroblasts, human tendon cells, human astrocytes, human neonatal skin fibroblasts, human synovial stromal cells, human brain capillary pericytes, human renal mesangial cells, human cardiac fibroblasts, human aortic vascular smooth muscle cells, human osteoblasts, normal human skeletal muscle cells, human dental pulp stem cells, human nucleus pulposus cells, human annulus fibrosus cells, human ligament cells, human chondrocytes, human Kupffer cells, human sinusoidal endothelial cells, human bile duct epithelial cells, human adult skin fibroblasts, human bone marrow-derived mesenchymal stem cells, and human adipose-derived mesenchymal stem cells.
23. A human liver-like three-dimensional structure obtained by the method according to claim 22.
Citation Information
Patent Citations
Quinazolinone compositions for controlling gene expression associated with pathological processes
JP2006504769A
Human hepatic 3D co-culture model and uses thereof
US20170166870A1
Screenable liver disease models and methods
US20190316093A1
In vitro toxicity screening assay
WO2017067970A1
Heterospheroid containing human-derived cells
WO2017200111A1
Cited By
Microwell sheet
WO2026191887A1
